国: アイルランド
言語: 英語
ソース: HPRA (Health Products Regulatory Authority)
Sodium alginate; Sodium hydrogen carbonate; Calcium carbonate
Reckitt Benckiser Ireland Ltd
A02BX; A02BX13
Sodium alginate; Sodium hydrogen carbonate; Calcium carbonate
250 mg/133.5 mg/80 milligram(s)
Chewable tablet
Product not subject to medical prescription
Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD); alginic acid
Marketed
2004-12-22
Package leaflet: Information for the user Gaviscon Peppermint Chewable Tablets Sodium alginate 250mg, Sodium hydrogen carbonate 133.5mg, Calcium carbonate 80mg READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Always use this medicine exactly as described in this leaflet or as your doctor, pharmacist or nurse has told you. • Keep this leaflet. You may need to read it again. • Ask your pharmacist if you need more information or advice. • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. • You must talk to a doctor if you do not feel better or if you feel worse after 7 days. WHAT IS IN THE LEAFLET 1. What Gaviscon Peppermint Tablets are and what they are used for? 2. What you need to know before you take Gaviscon Peppermint Tablets 3. How to take Gaviscon Peppermint Tablets 4. Possible side-effects 5. How to store Gaviscon Peppermint Tablets 6. Contents of the pack and other information 1. WHAT GAVISCON PEPPERMINT TABLETS ARE AND WHAT THEY ARE USED FOR? Gaviscon Peppermint Tablets form a protective layer which floats above the contents of the stomach. This layer prevents stomach acid escaping from the stomach into the food pipe, thus relieving the burning feeling of heartburn and the feeling of discomfort in the throat and mouth. Heartburn may occur following meals (e.g. when eating fatty or spicy food) or during pregnancy, or in patients with symptoms related to an inflammation in the wall of the food pipe (e.g. difficult and/or painful swallowing, mouth sores, vomiting). Gaviscon Peppermint Tablets are used for the treatment of symptoms of gastro-oesophageal reflux such as acid regurgitation, heartburn and indigestion (related to reflux), for example, following meals or during pregnancy, and in patients with symptoms related to eosophagitis. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE GAVISCON PEPPERMINT TABLETS DO NOT TAKE GAVISCON P 完全なドキュメントを読む
Health Products Regulatory Authority 01 December 2020 CRN008V4D Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Gaviscon Peppermint Chewable Tablets Sodium alginate 250mg Sodium hydrogen Carbonate 133.5mgCalcium Carbonate 80mg 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains sodium alginate 250 mg, sodium hydrogen carbonate 133.5 mg and calcium carbonate 80 mg. Excipients: Aspartame (E951) 3.75 mg per tablet. For a full list of excipients, see Section 6.1. 3 PHARMACEUTICAL FORM Chewable tablet. An off-white to cream, slightly mottled tablet. Emboss obverse - sword and circle Emboss reverse - G250 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of symptoms of gastro-oesophageal reflux such as acid regurgitation, heartburn and indigestion (related to reflux), for example, following meals or during pregnancy, or in patients with symptoms related to oesophagitis. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Adults and children 12 years and over: Two to four tablets after meals and at bedtime (up to four times per day). Children under 12 years: Should be given only on medical advice. Duration of treatment: If symptoms do not improve after seven days, the clinical situation should be reviewed. SPECIAL PATIENT GROUPS Elderly: No dose modifications necessary for this age group. Hepatic Impairment: No modifications necessary. Renal Insufficiency: Caution if highly restricted salt diet is necessary (See section 4.4) METHOD OF ADMINISTRATION For oral use, after being thoroughly chewed. Health Products Regulatory Authority 01 December 2020 CRN008V4D Page 2 of 5 4.3 CONTRAINDICATIONS This medicinal product is contraindicated in patients with known or suspected hypersensitivity to sodium alginate, sodium bicarbonate, and calcium carbonate or to any of the excipients listed in section 6.1. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE If symptoms do not improve after seven days, the clinical situation should be reviewed. Sodium: This medicinal product contains 253 完全なドキュメントを読む